Reyvow (lasmiditan) — United Healthcare
migraine headaches with or without aura
Initial criteria
- Diagnosis of migraine headaches with or without aura
- Used for acute treatment of migraine
- age ≥ 18 years
Reauthorization criteria
- Documentation of positive clinical response to therapy
Approval duration
12 months